nach oben

Pediatric Drugs

Erschienen in:

01.02.2010 | Review Article

Optimizing Emetic Control in Children Receiving Antineoplastic Therapy

Beyond the Guidelines

verfasst von: Ms L. Lee Dupuis, Paul C. Nathan

Erschienen in: Pediatric Drugs | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Existing guidelines for the prevention of antineoplastic chemotherapy-induced nausea and vomiting (CINV) in children are constrained by the lack of robust evidence. Current guidelines recommend the use of a serotonin 5-HT₃ receptor antagonist plus a corticosteroid to prevent acute CINV. Consequently, antiemetic agents that are recommended for use in adult cancer patients do not appear in the current pediatric guidelines. In addition, there is no information to guide the selection of alternative antiemetic agents for children who either cannot receive the recommended agents or who do not respond adequately to the treatment. Possible barriers to adherence to the pediatric antiemetic selection guidelines that are currently available are discussed, and published pediatric experience with antiemetic agents recommended in the current adult antiemetic selection guidelines (dolasetron, tropisetron, palonosetron, aprepitant) is summarized in this review. The use of novel and emerging antiemetic therapeutic interventions {metopimazine, diphenhydramine (Benadryl®)-lorazepam (Avitan®)-dexamethasone (Decadron®) [BAD], nabilone, acupuncture, midazolam, olanzapine, mirtazapine, gabapentin, droperidol} in children are explored.

Roila F, Feyer P, Maranzano R, et al. Antiemetics in children receiving chemotherapy. Support Care Cancer 2005; 13: 129–31PubMed

Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guidelines for antiemetics in oncology: update 2006. J Clin Oncol 2006; 24: 2932–47PubMed

Robson H, Meyer S, Shalet S, et al. The anti-tumor effects of cytotoxics are modulated by glucocorticoids in human osteosarcoma in vitro [abstract]. Med Pediatr Oncol 1999; 33: 155

Weller M, Schmidt C, Roth W, et al. Chemotherapy of human malignant glioma: prevention of efficacy by dexamethasone? Neurology 1997; 48: 1704–9PubMed

Rieger J, Durka S, Streffer J, et al. Gemcitabine cytotoxicity of human malignant glioma cells: modulation by antioxidants, BCL-2 and dexamethasone. Eur J Pharmacol 1999; 365: 301–8PubMed

Mariotta M, Perewusnyk G, Koechli OR, et al. Dexamethasone-induced enhancement of resistance to ionizing radiation and chemotherapeutic agents in human tumor cells. Strahlenther Onkol 1999; 175: 392–6PubMed

Straathof CS, van den Bent MJ, Ma J, et al. The effect of dexamethasone on the uptake of cisplatin in 9L glioma and the area of brain around tumor. J Neurooncol 1998; 37: 1–8PubMed

Vardy J, Chiew KS, Galica J, et al. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 2006; 94: 1011–5PubMedPubMedCentral

Hochhauser CJ, Lewis M, Kamen BA, et al. Steroid-induced alterations of mood and behavior in children during treatment for acute lymphoblastic leukemia. Support Care Cancer 2005; 13: 967–74PubMed

10.

Bodey GP. Fungal infections complicating acute leukemia. J Chronic Dis 1966; 19: 667–87PubMed

11.

Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358–66PubMed

12.

Nucci M, Colombo AL. Risk factors for breakthrough candidemia. Eur J Clin Microbiol Infect Dis 2002; 21: 209–11PubMed

13.

Sayer HG, Longton G, Bowden R, et al. Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention. Blood 1994; 84: 1328–32PubMed

14.

Khan RB. Migraine-type headaches in children receiving chemotherapy and ondansetron. J Child Neurol 2002; 17: 857–8PubMed

15.

Watanabe H, Hasegawa A, Shinozaki T, et al. Possible cardiac side effects of granisetron, an antiemetic agent, in patients with bone and soft-tissue sarcomas receiving cytotoxic chemotherapy. Cancer Chemother Pharmacol 1995; 35: 278–82PubMed

16.

Buyukavci M, Olgun H, Ceviz N. The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia. Am J Clin Oncol 2005; 28: 201–4PubMed

17.

Pinarli FG, Elli M, Dagdemir A, et al. Electrocardiographic findings after 5-HT3 receptor antagonists and chemotherapy in children with cancer. Pediatr Blood Cancer 2006; 47: 567–71PubMed

18.

Coppes MJ, Yanofsky R, Pritchard S, et al. Safety, tolerability, antiemetic efficacy, and pharmacokinetics of oral dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy. J Pediatr Hematol Oncol 1999; 21: 274–83PubMed

19.

Kris MG, Hesketh PJ, Herrstedt J, et al. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy [published erratum appears in Support Care Cancer 2005 Jul; 13 (7): 562]. Support Care Cancer 2005; 13: 85–96PubMed

20.

Antonarakis ES, Evans JL, Heard GF, et al. Prophylaxis of acute chemotherapy-induced nausea and vomiting in children with cancer: what is the evidence? Pediatr Blood Cancer 2004; 43: 651–8PubMed

21.

Bleiberg H, Van Belle S, Paridaens R, et al. Compassionate use of a 5-HT3-receptor antagonist, tropisetron, in patients refractory to standard antiemetic treatment. Drugs 1992; 43Suppl. 3: 27–32PubMed

22.

Gershanovich M, Kolygin B, Pirgach N. Tropisetron in the control of nausea and vomiting induced by combined cancer chemotherapy in children. Ann Oncol 1993; 4Suppl. 3: 35–7PubMed

23.

Hachimi-Idrissi S, De Schepper J, Maurus R, et al. Prevention of emesis by ICS 205–930 in children receiving cytotoxic chemotherapy. Eur J Cancer 1993; 29A: 854–6PubMed

24.

Suarez A, Stettler ER, Rey E, et al. Safety, tolerability, efficacy and plasma concentrations of tropisetron after administration at five dose levels to children receiving cancer chemotherapy. Eur J Cancer 1994; 30A: 1436–41PubMed

25.

Rosso P, Cordero di Montezemolo L, Vivenza C, et al. Efficacy of tropisetron (Navoban) in controlling emesis induced in children by anti-cancer therapy. Tumori 1994; 80: 459–63PubMed

26.

Benoit Y, Hulstaert F, Vermylen C, et al. Control of nausea and vomiting by Navoban (tropisetron) in 131 children receiving cytotoxic chemotherapy. Anticancer Drugs 1995; 6Suppl. 1: 9–14PubMed

27.

Stiakaki E, Savvas S, Lydaki E, et al. Ondansetron and tropisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy. Pediatr Hematol Oncol 1999; 16: 101–8PubMed

28.

Uysal KM, Olgun N, Sarialioglu F. Tropisetron in the prevention of chemotherapy-induced acute emesis in pediatric patients. Turk J Pediatr 1999; 41: 207–18PubMed

29.

Aksoylar S, Akman SA, Ozgenc F, et al. Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy. Pediatr Hematol Oncol 2001; 18: 397–406PubMed

30.

Cappelli C, Ragni G, De Pasquale MD, et al. Tropisetron: optimal dosage for children in prevention of chemotherapy-induced vomiting. Pediatr Blood Cancer 2005; 45: 48–53PubMed

31.

Forni C, Ferrari S, Loro L, et al. Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions. Support Care Cancer 2000; 8: 131–3PubMed

32.

Kaiser R, Sezer O, Papies A, et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 2002; 20: 2805–11PubMed

33.

Tremblay PB, Kaiser R, Sezer O, et al. Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol 2003; 21: 2147–55PubMed

34.

Gralla RJ, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase II trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14: 1570–7PubMed

35.

Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor anagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003; 98: 2473–82PubMed

36.

Einhorn LH, Brames MJ, Dreicer R, et al. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 2007; 15: 1293–300PubMed

37.

Adel N, Lucarelli C, Khan A, et al. Evaluating the use of palonosetron in pediatric patients for the prevention of chemotherapy induced nausea and vomiting (CINV). 40th Midyear Clinical Meeting of the American Society of Health-System Pharmacists; 2005 Dec 4–8; Las Vegas (NV)

38.

Kadota R, Shen V, Messinger Y. Safety, pharmacokinetics, and efficacy of palonosetron in pediatric patients: a multicenter, stratified, double-blind, phase 3, randomized study [abstract]. J Clin Oncol 2007; 25 Suppl.: 9570

39.

Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multi-national, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin. The Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21: 4112–9PubMed

40.

Smith AR, Repka TL, Weigel BJ. Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents. Pediatr Blood Cancer 2005; 45: 857–60PubMed

41.

Vianello O, Manfredini L, Miano M, et al. Effect of aprepitant on antiemetic protection in adolescents with cancer receiving highly emetogenic chemotherapy: a preliminary experience [abstract]. Support Care Cancer 2005; 13: 422

42.

Ouellet G, Therrien R. Utilisation de l’aprepitant pour les nausees et les vomissements refractaires secondaires a la chimiotherapie chez une adolescente. Pharmactuel 2005; 38: 220–5

43.

Gore L, Chawla SP, Petrilli AS, et al. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer 2009; 52: 242–7PubMed

44.

Murphy C, Shah N, Milla P, et al. NK1 receptor antagonism ameliorates nausea and emesis in typical and atypical variants of treatment refractory cyclical vomiting syndrome [abstract]. J Pediatr Gastroenterol 2006; 42: E13–4

45.

Dupuis LL, Lingertat-Walsh K, Walker SE. Stability of an extemporaneous oral liquid aprepitant formulation. Support Care Cancer 2009; 17: 701–6PubMed

46.

Merck Frosst Canada Ltd. Product monograph: Emend® aprepitant capsules 80 and 125 mg [online]. Available from URL: http://www.merckfrosst.ca/assets/en/pdf/products/EMEND_0810-a_124638-E.pdf [Accessed 2009 Nov 30]

47.

Nygren P, Hande K, Petty KJ, et al. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol 2005; 55: 609–16PubMed

48.

Herrstedt J, Sigsgaard T, Boesgaard M, et al. Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med 1993; 328: 1076–80PubMed

49.

Herrstedt J, Sigsgaard T, Handberg J, et al. Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer. J Clin Oncol 1997; 15: 1690–6PubMed

50.

Herrstedt J, Sigsgaard TC, Nielsen HA, et al. Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy. Support Care Cancer 2007; 15: 417–26PubMed

51.

Lebeau B, Depierre A, Giovannini M, et al. The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. the French Ondansetron Study Group. Ann Oncol 1997; 8: 887–92PubMed

52.

Bloch J, Rixe O, Meric JB, et al. Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy. Curr Med Res Opin 2005; 21: 1763–71PubMed

53.

Khamales S, Bethune-Volters A, Chidiac J, et al. A randomized, double-blind trial assessing the efficacy and safety of sublingual metopimazine and ondansetron in the prophylaxis of chemotherapy-induced delayed emesis. Anticancer Drugs 2006; 17: 217–24PubMed

54.

Nathan PC, Tomlinson G, Dupuis LL, et al. A pilot study of ondansetron plus metopimazine versus ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial N-of-1 trials design. Support Care Cancer 2006; 14: 268–76PubMed

55.

Debray H, Guihard J, Peyramond D, et al. Traitement des vomissements du nourrisson et de l’infant lies a une pathologie infectieuse aigue. Ann Pediatr (Paris) 1990; 37: 683–7

56.

Jones E, Koyama T, Ho RH, et al. Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy. Pediatr Blood Cancer 2007; 48: 330–2PubMed

57.

Dix S, Cord M, Howard S, et al. Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy. Bone Marrow Transplant 1999; 24: 561–6PubMed

58.

Olsen E, Thompson A. Unique anti-emetic management in the pediatric bone marrow transplant patients [abstract]. J Pediatr Hematol Oncol 2005; 27: 462

59.

Tramer MR, Carroll D, Campbell FA, et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001; 323: 16–21PubMedPubMedCentral

60.

Davis M, Maida V, Daeninck P, et al. The emerging role of cannabinoid neuromodulators in syptom management. Support Care Cancer 2007; 15: 63–71PubMed

61.

Dupuis LL, Nathan PC. Options for the prevention and management of acute chemotherapy-induced nausea and vomiting in children. Pediatr Drugs 2003; 5: 597–613

62.

Parfitt A. Acupuncture as an antiemetic treatment. J Altern Complement Med 1996; 2: 167–74, discussion 175-7PubMed

63.

Vickers AJ. Can acupuncture have specific effects on health? A systematic review of acupuncture antiemesis trials. J R Soc Med 1996; 89: 303–11PubMedPubMedCentral

64.

Ezzo JM, Richardson MA, Vickers A, et al. Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting. Cochrane Database Syst Rev 2006; (2): CD002285

65.

Molassiotis A, Helin AM, Dabbour R, et al. The effects of P6 acupressure in the prophylaxis of chemotherapy-related nausea and vomiting in breast cancer patients. Complement Ther Med 2007; 15: 3–12PubMed

66.

Reindl TK, Geilen W, Hartmann R, et al. Acupuncture against chemotherapy-induced nausea and vomiting in pediatric oncology: interim results of a multicenter crossover study. Support Care Cancer 2006; 14: 172–6PubMed

67.

Jones E, Isom S, Kemper KJ, et al. Acupressure for chemotherapy-associated nausea and vomiting in children. J Soc Integr Oncol 2008; 6: 141–5PubMed

68.

Pirl WF, Roth AJ. Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report. Psychooncology 2000; 9: 84–7PubMed

69.

Srivastava M, Brito-Dellan N, Davis MP, et al. Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manage 2003; 25: 578–82PubMed

70.

Passik SD, Kirsh KL, Theobald DE, et al. A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manage 2003; 25: 485–8PubMed

71.

Passik SD, Lundberg J, Kirsh KL, et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage 2002; 23: 526–32PubMed

72.

Passik SD, Navari RM, Jung SH, et al. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Investigation 2004; 22: 383–8PubMed

73.

Navari RM, Einhorn LH, Loehrer Sr PJ, et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group Study. Support Care Cancer 2007; 15: 1285–91PubMed

74.

Malone RP, Cater J, Sheikh RM, et al. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 2001; 40: 887–94PubMed

75.

Kemner C, Willemsen-Swinkels SH, de Jonge M, et al. Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol 2002; 22: 455–60PubMed

76.

Guttuso Jr T, Roscoe J, Griggs J. Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. Lancet 2003; 361: 1703–5PubMed

77.

Pandey CK, Priye S, Ambesh SP, et al. Prophylactic gabapentin for prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: a randomized, double-blind, placebo-controlled study. J Postgrad Med 2006; 52: 97–100PubMed

78.

Ho KY. Gabapentin for postoperative nausea and vomiting prophylaxis. J Postgrad Med 2006; 52: 230–1PubMed

79.

Mandala M, Cremonesi M, Rocca A, et al. Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: a phase II study. Support Care Cancer 2005; 13: 375–80PubMed

80.

Pae CU. Low-dose mirtazapine may be successful treatment option for severe nausea and vomiting. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1143–5PubMed

81.

Kim SW, Shin IS, Kim JM, et al. Mirtazapine for severe gastroparesis unresponsive to conventional prokinetic treatment. Psychosomatics 2006; 47: 440–2PubMed

82.

Rohde A, Dembinski J, Dorn C. Mirtazapine (Remergil) for treatment resistant hyperemesis gravidarum: rescue of a twin pregnancy. Arch Gynecol Obstet 2003; 268: 219–21PubMed

83.

Guclu S, Gol M, Dogan E, et al. Mirtazapine use in resistant hyperemesis gravidarum: report of three cases and review of the literature. Arch Gynecol Obstet 2005; 272: 298–300PubMed

84.

Caldis EV, Gair RD. Mirtazapine for treatment of nausea induced by selective serotonin reuptake inhibitors [letter]. Can J Psychiatry 2004; 49: 707PubMed

85.

Teixeira FV, Novaretti TM, Pilon B, et al. Mirtazapine (Remeron) as treatment for non-mechanical vomiting after gastric bypass. Obes Surg 2005; 15: 707–9PubMed

86.

Theobald DE, Kirsh KL, Holtsclaw E, et al. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage 2002; 23: 442–7PubMed

87.

Thompson DS. Mirtazapine for the treatment of depression and nausea in breast and gynecological oncology. Psychosomatics 2000; 41: 356–9PubMed

88.

Kast RE, Foley KF. Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. Eur J Cancer Care 2007; 16: 351–4

89.

Posey DJ, Guenin KD, Kohn AE, et al. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. J Child Adolesc Psychopharmacol 2001; 11: 267–77PubMed

90.

Albertini G, Polito E, Sara M, et al. Compulsive masturbation in infantile autism treated by mirtazapine. Pediatr Neurol 2006; 34: 417–8PubMed

91.

Haapasalo-Pesu KM, Vuola T, Lahelma L, et al. Mirtazapine in the treatment of adolescents with major depression: an open-label, multicenter pilot study. J Child Adolesc Psychopharmacol 2004; 14: 175–84PubMed

92.

Findling RL, McNamara NK, Stansbrey RJ, et al. The relevance of pharmacokinetic studies in designing efficacy trials in juvenile major depression. J Child Adolesc Psychopharmacol 2006; 16: 131–45PubMed

93.

Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007; 297: 1683–96PubMed

94.

Lewis GO, Bernath AM, Ellison NM, et al. Double-blind crossover trial of droperidol, metoclopramide, and prochlorperazine as antiemetics in cisplatin therapy. Clin Pharmacy 1984; 3: 618–21

95.

Saller R, Hellenbrecht D. High doses of metoclopramide or droperidol in the prevention of cisplatin-induced emesis. Eur J Cancer Clin Oncol 1986; 22: 1199–203PubMed

96.

Nuttall GA, Eckerman KM, Jacob KA, et al. Does low-dose droperidol administration increase the risk of drug-induced QT prolongation and torsade de pointes in the general surgical population? Anesthesiology 2007; 107: 531–6PubMed

97.

Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann Oncol 1998; 9: 811–9

Titel: Optimizing Emetic Control in Children Receiving Antineoplastic Therapy
Beyond the Guidelines
verfasst von: Ms L. Lee Dupuis
Paul C. Nathan
Publikationsdatum: 01.02.2010
Verlag: Springer International Publishing
Erschienen in: Pediatric Drugs / Ausgabe 1/2010
Print ISSN: 1174-5878
Elektronische ISSN: 1179-2019
DOI: https://doi.org/10.2165/11316190-000000000-00000

Neu im Fachgebiet Pädiatrie

23.04.2024 | Typ-1-Diabetes | Nachrichten

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Optimizing Emetic Control in Children Receiving Antineoplastic Therapy

Beyond the Guidelines

Abstract

Neu im Fachgebiet Pädiatrie

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Pädiatrie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2010

Juvenile Myelomonocytic Leukemia

Bosentan

Breastfeeding in HIV-Positive Women

Juvenile-Onset Clinically Amyopathic Dermatomyositis

Adverse Effects of Immunosuppression in Pediatric Solid Organ Transplantation

Neu im Fachgebiet Pädiatrie

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Pädiatrie